| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNCI/DJX097 |
| P698 | PubMed publication ID | 29546344 |
| P50 | author | Vivek H. Murthy | Q15177638 |
| Daniel Sterman | Q49967205 | ||
| Vivek Murthy | Q60631289 | ||
| Janna Minehart | Q86751113 | ||
| P2093 | author name string | Janna Minehart | |
| P2860 | cites work | Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment | Q46341133 |
| Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. | Q46421937 | ||
| Human Langerhans cells are immature in melanoma sentinel lymph nodes. | Q49217066 | ||
| Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma | Q50481182 | ||
| Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. | Q50889747 | ||
| Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma | Q51045550 | ||
| Endobronchial ultrasound-guided transbronchial needle injection for local control of recurrent non-small cell lung cancer | Q52992129 | ||
| Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. | Q53641322 | ||
| Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus Macaques. | Q54839684 | ||
| Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients | Q57220173 | ||
| Intralymphatic Injection of Autoantigen in Type 1 Diabetes | Q57449002 | ||
| Analysis of Dendritic Cells in Sentinel Lymph Nodes of Patients With Endometrial and Patients With Cervical Cancers | Q58496721 | ||
| Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients | Q58619922 | ||
| Secondary Lymphoid-tissue Chemokine Is a Functional Ligand for the CC Chemokine Receptor CCR7 | Q24318384 | ||
| Cancer; a biological approach. I. The processes of control | Q24684974 | ||
| Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. | Q27323878 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity | Q29620119 | ||
| Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 | Q29620608 | ||
| B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells | Q29620717 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer | Q33418729 | ||
| Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer | Q33482453 | ||
| Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules | Q33637231 | ||
| Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. | Q33965681 | ||
| Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients | Q34075717 | ||
| Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells | Q34147162 | ||
| In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study | Q34194680 | ||
| Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+T-Cell Function in Melanoma Patients | Q34269134 | ||
| Dendritic-cell-based therapeutic cancer vaccines | Q34360094 | ||
| OX40 is a potent immune-stimulating target in late-stage cancer patients | Q34381674 | ||
| Going viral with cancer immunotherapy | Q34427647 | ||
| Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Q34478015 | ||
| Combination immunotherapy: a road map. | Q34552128 | ||
| Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients | Q34560857 | ||
| Immune surveillance of tumors | Q34579196 | ||
| Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). | Q34638359 | ||
| Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. | Q34824109 | ||
| The significance of OX40 and OX40L to T-cell biology and immune disease. | Q34979946 | ||
| Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy | Q35237202 | ||
| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 | ||
| The role of intratumoral and systemic IL-6 in breast cancer | Q38093468 | ||
| Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy | Q38266149 | ||
| Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. | Q38571694 | ||
| Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma | Q38912327 | ||
| Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics | Q39025906 | ||
| Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses | Q39457393 | ||
| Intratumoral injection of interleukin‐2 augments the local and abscopal effects of radiotherapy in murine rectal cancer | Q39569395 | ||
| Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. | Q39636524 | ||
| Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha | Q39753147 | ||
| Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice | Q39881177 | ||
| Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells | Q40259678 | ||
| CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer | Q40327394 | ||
| Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes | Q40433302 | ||
| Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells | Q40498116 | ||
| Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity | Q40628602 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma | Q40702544 | ||
| Cancer vaccines based on the identification of genes encoding cancer regression antigens | Q41459252 | ||
| Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound | Q41491985 | ||
| Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients | Q41672999 | ||
| Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study | Q41740586 | ||
| Local immunomodulation for cancer therapy: Providing treatment where needed | Q41830647 | ||
| Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients | Q41967129 | ||
| Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma. | Q42112527 | ||
| Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma | Q42153454 | ||
| Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial | Q42797321 | ||
| Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells | Q42944333 | ||
| Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients | Q43453842 | ||
| Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma | Q46110144 | ||
| Clinical significance of the frequency of regulatory T cells in regional lymph node lymphocytes as a prognostic factor for non-small-cell lung cancer | Q46143389 | ||
| Viral Vector-Based Therapeutic Cancer Vaccines | Q35515080 | ||
| Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models | Q35549847 | ||
| Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma | Q35627237 | ||
| Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. | Q35690688 | ||
| Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation | Q35751954 | ||
| Induction of antigen-specific T cell anergy: An early event in the course of tumor progression | Q35798927 | ||
| Tolerance, not immunity, crucially depends on IL-2. | Q35877199 | ||
| Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer | Q36004154 | ||
| Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness | Q36161355 | ||
| Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma | Q36174230 | ||
| Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. | Q36179663 | ||
| TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. | Q36350923 | ||
| Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation | Q36403539 | ||
| OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection | Q36537926 | ||
| The tumor-draining lymph node as an immune-privileged site | Q36593753 | ||
| Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. | Q36675055 | ||
| Immune cell profile of sentinel lymph nodes in patients with malignant melanoma – FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome | Q36686432 | ||
| Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy | Q36696647 | ||
| Depleting tumor-specific Tregs at a single site eradicates disseminated tumors | Q36891034 | ||
| Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. | Q36941194 | ||
| The host STING pathway at the interface of cancer and immunity | Q37042237 | ||
| T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy | Q37157984 | ||
| Tumor regulatory T cells potently abrogate antitumor immunity | Q37317190 | ||
| Signals arising from antigen-presenting cells | Q37357505 | ||
| Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center | Q37380454 | ||
| Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial | Q37385677 | ||
| Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection | Q37397827 | ||
| Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression | Q37428061 | ||
| Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial | Q37429172 | ||
| Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node | Q37442008 | ||
| Fulminant Myocarditis with Combination Immune Checkpoint Blockade | Q37595462 | ||
| Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo | Q37655753 | ||
| A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma | Q37665688 | ||
| Oncolytic virotherapy | Q38025263 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P577 | publication date | 2017-12-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses | |
| P478 | volume | 109 |
| Q90570401 | Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot" | cites work | P2860 |
Search more.